Australian Centre for
HIV and Hepatitis Virology Research

Advertisement OCT/26 - The Australian

Australian Centre for HIV and Hepatitis Virology Research (ACH4)
CALL FOR EXPRESSIONS OF INTEREST (EOI)

Over the past 23 years, ACH4 has supported translational research in human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and more recently, human T-lymphotropic virus type-1 (HTLV-1). In 2027, ACH4 will continue to support translational research into these four viral infections.

ACH4 is seeking expressions of interest (EOI) in applied research from qualified scientists to fund research projects focused on: i) development of vaccine candidates for HIV, HBV subtypes, HCV or HTLV-1; ii) development of prevention strategies, including HIV microbicides and pre-exposure prophylaxis (PrEP); iii) cure and treatment interventions for HIV, HBV, or HTLV-1, including immunotherapy iv) novel diagnostics and prognostics for HIV, HBV, HCV, HTLV-1 or hepatitis B/C/HIV/HTLV-1 co-infection; v) molecular tools for tracking epidemics caused by these viruses; and vi) development of new tests for supporting vaccine and antiviral trials for these four viruses . **Basic research is not eligible for funding**, nor are projects focused on developing new direct-acting antivirals for HCV.

Research projects based on clinical data and specimens from patients with HIV, HCV and HBV stored by the Immunovirology Research Network (IVRN) are encouraged.

The grants are intended to complement and translate basic research projects in the virology and immunology of HIV, HBV, HCV and HTLV-1 that are commonly funded by other granting bodies such as NHMRC. **The ACH4 grants are not intended for the basic research itself.** A few awards will be available for seed funding of applications that are viewed by the Scientific Advisory Committee (SAC) to be exciting & innovative ideas that have the potential for longer-term translation.

Funding is available from 1 January 2027 to 30 October 2027 for grants up to $50,000.

Eligibility: Applications are invited from Australian investigators (citizens or permanent residents), whether employed at an Australian university, hospital, research institute or other similar institution conducting research in Australia. Investigators who are currently designated as Chief Investigator A (CIA) on another grant application funded through the Australian Government Department of Health G05055 Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) Research Program are not eligible to apply in this capacity.
To ensure broad participation and equitable access to funding opportunities, each eligible CIA may submit only one application under this funding round. Collaborative approaches are strongly encouraged and applications from national multidisciplinary and multi-institutional collaborative groups are particularly welcomed.

Applications must be submitted by the Administering Institute or University Research Officer via the ACH4 online application portal: https://ach4.org.au/apply/ if you have any issues with the portal please contact: joanne.reidy@wimr.org.au. ACH4 grants will be awarded to the administering organisation through which the CI-A submits their application. All awards will be governed by a participant agreement (between the participant organisation and The Westmead Institute for Medical Research representing ACH4).
All administering organisations awarded a grant will be required to enter such an agreement.

Guidelines explaining further details & eligibility criteria of this funding is available at ach4.org.au/apply/ or: Joanne Reidy - Administration Officer, ACH4
The Westmead Institute for Medical Research
PO Box 412, Westmead NSW 2145 Phone: +61 2 9843 9175 / Email: joanne.reidy@wimr.org.au

Expressions of Interest close at 5:00 pm AEDT on Friday 13 November 2026
Areas of Research: HIV, Hepatitis B, Hepatitis C and HTLV-1